infobae – Seven Infant Heart Transplant Patients Show No Rejection Thanks to a Therapy Developed at Gregorio Marañón
Researchers from the Immunoregulation Laboratory at Hospital General Universitario Gregorio Marañón have successfully treated seven infants who underwent heart transplantation with a treatment unique worldwide. The therapy is based on a cellular approach using thyTreg cells to prevent immune rejection and potentially extend the survival of the transplanted organ indefinitely, thereby prolonging the patient’s life. […]
rtve – Three Years Later, Irene’s Heart Beats Rejection-Free
Today on For Three Reasons, we visit Hospital General Universitario Gregorio Marañón, where Irene underwent a heart transplant three years ago. Her heart continues to function without complications thanks to a cellular therapy that helps prolong the life of the transplanted organ. We speak with Rafael Correa Rocha, Director of the Immunoregulation Laboratory at Hospital […]
El Español – The Spanish Biotech Company Aiming to Cure Autoimmune Diseases
Thytech has successfully developed a pioneering cell therapy to prevent rejection in infant heart transplant recipients. The startup is now seeking to expand its applications to treat autoimmune diseases in adults. Congenital heart defects affect one in every 100 newborns. They are the most common birth-related conditions in Spain, with around 4,000 new cases each […]
Europapress – Banco Sabadell Leads the €350,000 First Investment Round of Medtech Company Thytech
Banco Sabadell has led the first investment round of medtech company Thytech, which closed at €350,000. This marks the second investment under the fourth edition of the BStartup Health program, which received applications from 121 startups. Thytech was founded by researchers from the Health Research Institute of Hospital General Universitario Gregorio Marañón (IISGM) in Madrid […]
El Referente – Medtech Company Thytech Raises €350,000 in Its First Investment Round
The deal was led by BStartup, Banco Sabadell’s startup investment unit, and will support the Gregorio Marañón Hospital spin-off in advancing its immune-regulation treatment. Thytech, a startup founded by researchers from the Hospital General Universitario Gregorio Marañón in Madrid, has just closed its first €350,000 funding round. The round was led by Banco Sabadell through […]
VIAempresa – Sabadell Leads Thytech’s First Investment Round
The Madrid-based medtech company Thytech has raised €350,000 to advance its cell therapy aimed at preventing transplant rejection. BStartup Health, the Banco Sabadell program dedicated to financing early-stage healthcare companies, has led the €350,000 funding round for Thytech, a company specialized in cell therapy. The round also included participation from Genesis Biomed and other private […]
El Plural – Banco Sabadell Leads the First Investment Round of Medtech Company Thytech
In the €350,000 funding round, participants included Banco Sabadell’s BStartup, Genesis Biomed, and private investors. A cell therapy designed to prevent transplant rejection, treat autoimmune diseases, and even reduce mortality in severe COVID-19 patients — this is the unique, world-first treatment developed by Thytech, a startup founded by researchers from Hospital General Universitario Gregorio Marañón. […]
Bolasamanía – Economy/Finance.- Banco Sabadell Leads the First €350,000 Investment Round of Medtech Company Thytech
Banco Sabadell has led the first investment round of medtech company Thytech, which closed at €350,000. This marks the second investment from the fourth edition of the BStartup Health program, which received applications from 121 startups. Thytech was founded by researchers from the Health Research Institute of Hospital Gregorio Marañón (IISGM) in Madrid and has […]
Treg Directed Therapies – Expand the Application of Treg Therapies into a Clinical Reality
Accelerate the Translation of Modulator & Treg Cell Therapies to Redefine Immune Tolerance for Autoimmune, Inflammatory, & Neurodegenerative Diseases With Nobel Prize recognition, clinical advances by Nektar Therapeutics and ORCA-T’s potential as the first FDA-approved Treg cell therapy, Treg therapies are making waves. At the 8th Treg-Directed Therapies Summit, Treg experts including Quell Therapeutics, Nektar Therapeutics, Sanofi, Yale and more, converge to overcome key challenges from cell targeting, Treg mechanisms of […]
El Confidencial – Gregorio Marañón Creates a Pioneering Treatment Against Transplant Rejection
A team of researchers at Hospital General Universitario Gregorio Marañón has developed a world-pioneering cell-based treatment to prevent transplant rejection. The technique is already being used to treat three infant heart transplant recipients, all of whom are progressing favorably. The treatment, developed entirely at this public hospital in Madrid over the past six years, helps […]
